日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline

正电子发射断层扫描（PET）作为基线CA19-9水平正常的转移性胰腺癌患者的预测指标。

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdw177
Ramanathan, R K; Korn, R L; Chiorean, E G; Liu, H; Von Hoff, D D
胰腺癌
肿瘤
肿瘤免疫
发表日期：2016
文献求助 收藏

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

在转移性胰腺癌患者中，一项随机III期临床试验（MPACT）比较了每周一次的白蛋白结合型紫杉醇联合吉西他滨与单用吉西他滨治疗的疗效，结果显示，CA19-9在8周时的下降可作为总生存期的预测指标。

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdw006
Chiorean, E G; Von Hoff, D D; Reni, M; Arena, F P; Infante, J R; Bathini, V G; Wood, T E; Mainwaring, P N; Muldoon, R T; Clingan, P R; Kunzmann, V; Ramanathan, R K; Tabernero, J; Goldstein, D; McGovern, D; Lu, B; Ko, A
胰腺癌
肿瘤
肿瘤免疫
发表日期：2016
文献求助 收藏

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas

一项随机 III 期试验中，每周一次的纳米白蛋白紫杉醇联合吉西他滨与单独使用吉西他滨治疗转移性胰腺腺癌患者的正电子发射断层扫描反应评估

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdw020
Ramanathan, R K; Goldstein, D; Korn, R L; Arena, F; Moore, M; Siena, S; Teixeira, L; Tabernero, J; Van Laethem, J-L; Liu, H; McGovern, D; Lu, B; Von Hoff, D D
肿瘤
肿瘤免疫
发表日期：2016
文献求助 收藏

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

copanlisib (BAY 80-6946) 是一种静脉注射的泛 I 类磷脂酰肌醇 3-激酶抑制剂，用于治疗晚期实体瘤和非霍奇金淋巴瘤患者，这是首次人体 I 期研究。

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdw282
Patnaik, A; Appleman, L J; Tolcher, A W; Papadopoulos, K P; Beeram, M; Rasco, D W; Weiss, G J; Sachdev, J C; Chadha, M; Fulk, M; Ejadi, S; Mountz, J M; Lotze, M T; Toledo, F G S; Chu, E; Jeffers, M; Peña, C; Xia, C; Reif, S; Genvresse, I; Ramanathan, R K
信号转导
淋巴瘤
发表日期：2016
文献求助 收藏

Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT

采用间歇性奥沙利铂治疗策略可延长治疗失败时间：CONcePT 研究结果

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdu107
Hochster, H S; Grothey, A; Hart, L; Rowland, K; Ansari, R; Alberts, S; Chowhan, N; Ramanathan, R K; Keaton, M; Hainsworth, J D; Childs, B H
发表日期：2014
文献求助 收藏

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.

ficlatuzumab 单药治疗或与厄洛替尼联合治疗难治性晚期实体瘤和多发性骨髓瘤的 I 期临床试验

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/bjc.2014.290
Patnaik A, Weiss G J, Papadopoulos K P, Hofmeister C C, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo F C, Cotreau M M, Ramanathan R K
肿瘤
骨髓瘤
肿瘤免疫
发表日期：2014
文献求助 收藏

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

针对晚期实体瘤和B细胞恶性肿瘤患者的泛PI3K/mTORC血管靶向前药SF1126的I期药代动力学和药效学研究

期刊:European Journal of Cancer
影响因子:7.1
doi:10.1016/j.ejca.2012.06.027
Mahadevan, D; Chiorean, E G; Harris, W B; Von Hoff, D D; Stejskal-Barnett, A; Qi, W; Anthony, S P; Younger, A E; Rensvold, D M; Cordova, F; Shelton, C F; Becker, M D; Garlich, J R; Durden, D L; Ramanathan, R K
B细胞
肿瘤
mTOR
肿瘤免疫
细胞生物学
免疫/内分泌
发表日期：2012
文献求助 收藏

A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer

一项随机II期临床试验，比较吉西他滨联合索拉非尼与单用索拉非尼治疗转移性胰腺癌患者的疗效

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-011-9658-9
El-Khoueiry, A B; Ramanathan, R K; Yang, D Y; Zhang, W; Shibata, S; Wright, J J; Gandara, D; Lenz, H J
胰腺癌
肿瘤
肿瘤免疫
发表日期：2012
文献求助 收藏